Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Impact of hydroxyurea on clinical events in the BABY HUG trial.

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Blood. 2012 Nov 22;120(22):4304-10; quiz 4448. doi: 10.1182/blood-2012-03-419879. Epub 2012 Aug 22. Erratum in: Blood. 2016 Dec 15;128(24):2869.

2.

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; BABY HUG investigators.

Lancet. 2011 May 14;377(9778):1663-72. doi: 10.1016/S0140-6736(11)60355-3.

3.

Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.

Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE; Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH).

Am J Hematol. 2013 Nov;88(11):932-8. doi: 10.1002/ajh.23547. Epub 2013 Aug 30.

4.

Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.

Lebensburger JD, Miller ST, Howard TH, Casella JF, Brown RC, Lu M, Iyer RV, Sarnaik S, Rogers ZR, Wang WC; BABY HUG Investigators.

Pediatr Blood Cancer. 2012 Oct;59(4):675-8. doi: 10.1002/pbc.24037. Epub 2011 Dec 20.

5.

Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia.

Miller ST, Rey K, He J, Flanagan J, Fish BJ, Rogers ZR, Wang WC, Ware RE; BABY HUG Investigators.

Pediatr Blood Cancer. 2012 Jul 15;59(1):170-2. doi: 10.1002/pbc.23244. Epub 2011 Jul 8.

6.

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Pediatrics. 2013 Oct;132(4):677-83. doi: 10.1542/peds.2013-0333. Epub 2013 Sep 2.

7.

The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.

Thompson BW, Miller ST, Rogers ZR, Rees RC, Ware RE, Waclawiw MA, Iyer RV, Casella JF, Luchtman-Jones L, Rana S, Thornburg CD, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik S, Howard TH, Luck L, Wang WC.

Pediatr Blood Cancer. 2010 Feb;54(2):250-5. doi: 10.1002/pbc.22269.

8.

Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.

McGann PT, Flanagan JM, Howard TA, Dertinger SD, He J, Kulharya AS, Thompson BW, Ware RE; BABY HUG Investigators.

Pediatr Blood Cancer. 2012 Aug;59(2):254-7. doi: 10.1002/pbc.23365. Epub 2011 Oct 19.

9.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

10.

Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.

Alvarez O, Miller ST, Wang WC, Luo Z, McCarville MB, Schwartz GJ, Thompson B, Howard T, Iyer RV, Rana SR, Rogers ZR, Sarnaik SA, Thornburg CD, Ware RE; BABY HUG Investigators.

Pediatr Blood Cancer. 2012 Oct;59(4):668-74. doi: 10.1002/pbc.24100. Epub 2012 Jan 31.

11.

Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.

Blood. 1999 Sep 1;94(5):1550-4.

12.

Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.

Rees AL.

J Pediatr Oncol Nurs. 2016 Sep;33(5):339-44. doi: 10.1177/1043454215614962. Epub 2015 Nov 26.

PMID:
26611755
13.

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.

JAMA. 2003 Apr 2;289(13):1645-51. Erratum in: JAMA. 2003 Aug 13;290(6):756.

PMID:
12672732
14.

Hydroxyurea and growth in young children with sickle cell disease.

Rana S, Houston PE, Wang WC, Iyer RV, Goldsmith J, Casella JF, Reed CK, Rogers ZR, Waclawiw MA, Thompson B; BABY HUG Investigators.

Pediatrics. 2014 Sep;134(3):465-72. doi: 10.1542/peds.2014-0917. Erratum in: Pediatrics. 2015 Sep;136(3):584.

15.

Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.

Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.

Hemoglobin. 2012;36(4):323-32. doi: 10.3109/03630269.2012.697948.

PMID:
22734586
16.

Use of hydroxyurea in children with sickle cell disease: what comes next?

Ohene-Frempong K, Smith-Whitley K.

Semin Hematol. 1997 Jul;34(3 Suppl 3):30-41. Review.

PMID:
9317199
17.

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Arch Dis Child. 2013 Nov;98(11):908-14. doi: 10.1136/archdischild-2012-302387. Epub 2013 Aug 30. Review.

18.

Hydroxyurea therapy in children severely affected with sickle cell disease.

Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.

J Pediatr. 1996 Jun;128(6):820-8.

PMID:
8648542
19.

Immunologic effects of hydroxyurea in sickle cell anemia.

Lederman HM, Connolly MA, Kalpatthi R, Ware RE, Wang WC, Luchtman-Jones L, Waclawiw M, Goldsmith JC, Swift A, Casella JF; BABY HUG Investigators.

Pediatrics. 2014 Oct;134(4):686-95. doi: 10.1542/peds.2014-0571. Epub 2014 Sep 1.

20.

Long-term hydroxyurea treatment in young sickle cell patients.

Maier-Redelsperger M, Labie D, Elion J.

Curr Opin Hematol. 1999 Mar;6(2):115-20. Review.

PMID:
10088642

Supplemental Content

Support Center